Avoid common mistakes on your manuscript.
Past
Pancreaticoduodenectomy (PD) is a standardized resection for distal cholangiocarcinoma. If the tumor is located in the middle-third bile duct alone, bile duct resection (BDR) may be considered as an alternative approach. However, this tumor is rare, with an incidence of about 13% among all cholangiocarcinomas,1 and recent surveys have observed that BDR accounted for only 1.5–2.7% of resections for cholangiocarcinoma.2,3 Therefore, the oncologic benefit of BDR remains poorly understood.
Present
The authors conducted a multi-institutional retrospective study of 92 patients who underwent BDR (n = 38) or PD (n = 54) for middle-third cholangiocarcinoma.4 The short-term outcomes involving operation time, blood loss, complications, and mortality were better with BDR than with PD. The survival rate after BDR was significantly worse than after PD (38.8% vs 54.8% at 5 years; P = 0.035), and BDR was an independent factor deteriorating survival. Subgroup analysis in the BDR group, however, demonstrated that tumor < 15 mm and margin ≥ 10 mm lead to better survival, similar to the PD group.
Future
The data from this study demonstrated that middle-third cholangiocarcinoma remains a dreaded disease potentially affected by surgical procedure. Although BDR may be easy to use and patient friendly, it should be performed for strictly selected patients based on tumor length and expected ductal margin rather than patient risk. Thus, from the viewpoint of surgical oncology, a very small population of patients with cholangiocarcinoma seems to benefit from BDR. In reality, a prospective randomized study is impractical due to the rarity and inferiority of the tumor. Well-designed retrospective studies are needed for further integration of analysis.
References
Reding R, Buard JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded): results of the French Surgical Association Survey. Ann Surg. 1991;213:236–41.
Carroll JE Jr, Hurwitz ZM, Simons JP, et al. In-hospital mortality after resection of biliary tract cancer in the United States. HPB Oxf. 2010;12:62–7.
Strijker M, Belkouz A, van der Geest LG, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58:1048–55.
Jikei K, Ebata T, Mizuno T, et al. Oncologic reappraisal of bile duct resection for middle-third cholangiocarcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09157-3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ebata, T., Jikei, K. & Mizuno, T. ASO Author Reflections: Bile Duct Resection—Is It Beneficial for Distal Cholangiocarcinoma?. Ann Surg Oncol 28, 2000 (2021). https://doi.org/10.1245/s10434-020-09171-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09171-5